Johnson & Johnson might be the worst performing big pharma stock YTD, but there's upside possible for it in the remainder of 2024.Revenue growth guidance was upgraded and even with a downgrade in EPS ...
Source LinkJohnson & Johnson might be the worst performing big pharma stock YTD, but there's upside possible for it in the remainder of 2024.Revenue growth guidance was upgraded and even with a downgrade in EPS ...
Source Link
Comments